1H-Indene-1-carbonitrile, 2,3-dihydro-4,7-dimethoxy- | 1092350-31-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1H-Indene-1-carbonitrile, 2,3-dihydro-4,7-dimethoxy-
• 英文别名: 4,7-dimethoxy-2,3-dihydro-1H-indene-1-carbonitrile
• CAS: 1092350-31-6
• 化学式: C₁₂H₁₃NO₂
• 分子量: 203.24
• InChiKey: MZDQRVUYHHNXNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20180244611A1

  公开（公告）日：2018-08-30

  The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
• [EN] MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE<br/>[FR] MODULATEURS DE PROTÉINE RÉGULATRICE DE CONDUCTANCE TRANSMEMBRANAIRE DE LA FIBROSE KYSTIQUE ET PROCÉDÉS D'UTILISATION
  申请人：ABBVIE SARL

  公开号：WO2018154519A1

  公开（公告）日：2018-08-30

  The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention. In one embodiment, the compound is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, (I) wherein A1 is selected from the group consisting of X1, X2, X3, X4; R1, R2A, R2B, R2C, R2D, R3, R4,R5A, R5B, R5C, R5D, R6A, R6B, R6C, R6D, R7, R8, R9, R10, R11, R12, R13, and R14 are as described herein.